Literature DB >> 16032408

Polymorphisms in the promoter region of RANTES in Han Chinese and their relationship with systemic lupus erythematosus.

Dong Qing Ye1, Shi Gui Yang, Xiang Pei Li, Yi Song Hu, Jing Yin, Guo Qing Zhang, Hui Hui Liu, Qian Wang, Ke Chun Zhang, Ma Xia Dong, Xue Jun Zhang.   

Abstract

Systemic lupus erythematosus (SLE) is a complex multisystem autoimmune disease afflicting more than 600,000 individuals in China. RANTES (regulated on activation, normal T cell expressed and secreted, 17q11.2-q12) is a member of the proinflammatory cytokine family known as "chemokines". It plays an important role in the attraction and recruitment of lymphocytes, monocytes and eosinophils to sites of inflammation. A total of 146 SLE patients and 159 random healthy volunteer individuals in Han Chinese patients were enrolled in this study. Genotypes of RANTES -403 locus and -28 locus were observed to be different in all racial groups. The frequency of individuals who possessed G allele at -28 locus among SLE patients was not significantly different from that among normal controls. A total of seven compound genotypes at -403 locus and -28 locus were observed in this study. The frequency of this compound genotype (-403 G/G, -28 C/C) was different between the two groups. The distribution of genotypes and alleles at RANTES-403 locus was observed to be significantly different between renal damaged group and no renal damaged group (P<0.05), while there was no significant difference in distribution of genotypes and alleles at RANTES-28 locus between the two groups. These results suggest that (a) two genetic polymorphisms in the RANTES promoter do not correlate with SLE as individual polymorphisms. (b) interaction of the polymorphisms at two loci probably exerts a risk effect against SLE and (c) polymorphism at RANTES-403 locus is probably related with renal damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16032408     DOI: 10.1007/s00403-005-0581-9

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  13 in total

Review 1.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

2.  A study on the association of autoantibodies, chemokine, and its receptor with disease activity in systemic lupus erythematosus in North Indian population.

Authors:  Leishangthem Bidyalaxmi Devi; Archana Bhatnagar; Ajay Wanchu; Aman Sharma
Journal:  Rheumatol Int       Date:  2013-07-06       Impact factor: 2.631

3.  Increased serum RANTES in patients with systemic lupus erythematosus.

Authors:  Man-Man Lu; Juan Wang; Hai-Feng Pan; Gui-Mei Chen; Jing Li; Han Cen; Chen-Chen Feng; Dong-Qing Ye
Journal:  Rheumatol Int       Date:  2011-01-22       Impact factor: 2.631

4.  RANTES deficiency attenuates autoantibody-induced glomerulonephritis.

Authors:  Chun Xie; Kui Liu; Yuyang Fu; Xiangmei Qin; Geetha Jonnala; Tao Wang; Hong W Wang; Michael Maldonado; Xin J Zhou; Chandra Mohan
Journal:  J Clin Immunol       Date:  2010-10-01       Impact factor: 8.317

5.  Association of serum MIP-1alpha, MIP-1beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus.

Authors:  Luis M Vilá; María J Molina; Angel M Mayor; José J Cruz; Eddy Ríos-Olivares; Zilka Ríos
Journal:  Clin Rheumatol       Date:  2006-08-19       Impact factor: 2.980

Review 6.  Mechanisms of disease: regulation of RANTES (CCL5) in renal disease.

Authors:  Alan M Krensky; Yong-Tae Ahn
Journal:  Nat Clin Pract Nephrol       Date:  2007-03

Review 7.  Global trends, potential mechanisms and early detection of organ damage in SLE.

Authors:  Anselm Mak; David A Isenberg; Chak-Sing Lau
Journal:  Nat Rev Rheumatol       Date:  2012-12-11       Impact factor: 20.543

8.  Association of RANTES and MBL gene polymorphisms with systemic lupus erythematosus: a meta-analysis.

Authors:  Wang-Dong Xu; Hui Peng; Mo Zhou; Min Zhang; Bao-Zhu Li; Hai-Feng Pan; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

Review 9.  CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

Authors:  Dandan Lv; Yan Zhang; Ha-Jeong Kim; Lixing Zhang; Xiaojing Ma
Journal:  Cell Mol Immunol       Date:  2013-02-04       Impact factor: 11.530

Review 10.  The chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility.

Authors:  R Colobran; R Pujol-Borrell; M P Armengol; M Juan
Journal:  Clin Exp Immunol       Date:  2007-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.